A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant

por Wolz, Olaf-Oliver, Kays, Sarah-Katharina, Junker, Helga, Koch, Sven D., Mann, Philipp, Quintini, Gianluca, von Eisenhart-Rothe, Philipp, Oostvogels, Lidia
Publicado 2022

Absence of Non-Canonical, Inhibitory MYD88 Splice Variants in B Cell Lymphomas Correlates With Sustained NF-κB Signaling

por Cardona Gloria, Yamel, Bernhart, Stephan H., Fillinger, Sven, Wolz, Olaf-Oliver, Dickhöfer, Sabine, Admard, Jakob, Ossowski, Stephan, Nahnsen, Sven, Siebert, Reiner, Weber, Alexander N. R.
Publicado 2021

Putative link between Polo-like kinases (PLKs) and Toll-like receptor (TLR) signaling in transformed and primary human immune cells

por El Maadidi, Souhayla, Weber, Alexander N. R., Motshwene, Precious, Schüssler, Jan Moritz, Backes, Daniel, Dickhöfer, Sabine, Wang, Hui, Liu, Xiao, Garcia, Magno Delmiro, Taumer, Christoph, Soufi, Boumediene, Wolz, Olaf-Oliver, Klimosch, Sascha N., Franz-Wachtel, Mirita, Macek, Boris, Gay, Nicholas J.
Publicado 2019

HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy

por Nelde, Annika, Walz, Juliane Sarah, Kowalewski, Daniel Johannes, Schuster, Heiko, Wolz, Olaf-Oliver, Peper, Janet Kerstin, Cardona Gloria, Yamel, Langerak, Anton W., Muggen, Alice F., Claus, Rainer, Bonzheim, Irina, Fend, Falko, Salih, Helmut Rainer, Kanz, Lothar, Rammensee, Hans-Georg, Stevanović, Stefan, Weber, Alexander N. R.
Publicado 2016

Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189]

por Sáez-Llorens, Xavier, Lanata, Claudio, Aranguren, Elaine, Celis, Carlos R., Cornejo, Rubelio, DeAntonio, Rodrigo, Ecker, Lucie, Garrido, Diegi, Gil, Ana I., Gonzales, Marina, Hess-Holtz, Morgan, Leroux-Roels, Geert, Junker, Helga, Kays, Sarah-Katharina, Koch, Sven D., Lazzaro, Sandra, Mann, Philipp, Quintini, Gianluca, Srivastava, Barkha, Vahrenhorst, Dominik, von Eisenhart-Rothe, Philipp, Wolz, Olaf-Oliver, Oostvogels, Lidia
Publicado 2023

Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: A phase 1 randomized clinical trial

por Kremsner, Peter G., Mann, Philipp, Kroidl, Arne, Leroux-Roels, Isabel, Schindler, Christoph, Gabor, Julian J., Schunk, Mirjam, Leroux-Roels, Geert, Bosch, Jacobus J., Fendel, Rolf, Kreidenweiss, Andrea, Velavan, Thirumalaisamy P., Fotin-Mleczek, Mariola, Mueller, Stefan O., Quintini, Gianluca, Schönborn‑Kellenberger, Oliver, Vahrenhorst, Dominik, Verstraeten, Thomas, Alves de Mesquita, Margarida, Walz, Lisa, Wolz, Olaf‑Oliver, Oostvogels, Lidia
Publicado 2021

Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study

por Sáez-Llorens, Xavier, Lanata, Claudio, Aranguren, Elaine, Celis, Carlos R., Cornejo, Rubelio, DeAntonio, Rodrigo, Ecker, Lucie, Garrido, Diegi, Gil, Ana I., Gonzales, Marina, Hess-Holtz, Morgan, Leroux-Roels, Geert, Junker, Helga, Kays, Sarah-Katharina, Koch, Sven D., Lazzaro, Sandra, Mann, Philipp, Quintini, Gianluca, Srivastava, Barkha, Vahrenhorst, Dominik, von Eisenhart-Rothe, Philipp, Wolz, Olaf-Oliver, Oostvogels, Lidia
Publicado 2022

BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity

por Bittner, Zsófia Agnes, Liu, Xiao, Mateo Tortola, Maria, Tapia-Abellán, Ana, Shankar, Sangeetha, Andreeva, Liudmila, Mangan, Matthew, Spalinger, Marianne, Kalbacher, Hubert, Düwell, Peter, Lovotti, Marta, Bosch, Karlotta, Dickhöfer, Sabine, Marcu, Ana, Stevanović, Stefan, Herster, Franziska, Cardona Gloria, Yamel, Chang, Tzu-Hsuan, Bork, Francesca, Greve, Carsten L., Löffler, Markus W., Wolz, Olaf-Oliver, Schilling, Nadine A., Kümmerle-Deschner, Jasmin B., Wagner, Samuel, Delor, Anita, Grimbacher, Bodo, Hantschel, Oliver, Scharl, Michael, Wu, Hao, Latz, Eicke, Weber, Alexander N.R.
Publicado 2021